The advancement of regenerative dentistry is increasingly defined by the quality of biomaterials used and the ability to scale their production industrially without compromising clinical properties. Against this backdrop, the long-term partnership between VIVOLTA, a company specializing in medical electrospinning solutions, and Fibrothelium, a developer of silk protein-based biomaterials, represents a significant event for the guided bone regeneration (GBR) market.
The agreement focuses on the industrial production of electrospun components for the SimplySilk membrane — an innovative barrier material based on silk fibroin, designed for use in dental implantology, periodontology, and maxillofacial surgery.
Under the terms of the agreement, VIVOLTA becomes the exclusive contract manufacturer of the electrospun components for the SimplySilk membrane. Production will be carried out using the fully automated MediSpin platform, enabling commercial-scale manufacturing while strictly adhering to quality standards and regulatory requirements.
Automation of electrospinning is crucial for clinically oriented biomaterials, as it ensures reproducibility of structure, uniformity of fibers, and stability of mechanical properties — parameters that directly impact the predictability of bone tissue regeneration.
SimplySilk is a resorbable barrier membrane designed to create optimal conditions for bone formation by isolating the defect from soft tissues. The membrane is based on Fibrothelium’s silk fibroin technology and features a multi-layered architecture.
Two porous, fleece-like outer surfaces facilitate rapid soft tissue integration, while an optional dense core of silk fibroin slows biodegradation and enhances the mechanical stability of the structure. This combination maintains the barrier function of the membrane precisely during the period when it is clinically needed.
A fundamental distinction of SimplySilk from traditional GBR membranes is the complete absence of materials of animal origin. Unlike collagen membranes derived from animal tissues, SimplySilk eliminates the risk of pathogen transmission and ensures more predictable degradation timelines.
The biocompatible material PureSilk, which forms the basis of SimplySilk, demonstrates predictable and safe healing of bone defects. The membrane gradually resorbs in the body, eliminating the need for additional surgical intervention for its removal — a factor of significant importance for both patient comfort and reducing overall surgical burden.
Against the backdrop of a global increase in implant procedures and the rising prevalence of periodontal diseases, the demand for highly effective regenerative solutions continues to grow. Research indicates that over half of patients receiving dental implants require some form of bone grafting or guided bone regeneration.
The global market for guided bone regeneration membranes was valued at approximately $520 million USD in 2024 and is projected to nearly double, reaching around $950 million by 2033, with an annual growth rate of about 7.5%. This growth is driven by the demand for next-generation biomaterials capable of improving clinical outcomes and reducing complication rates in implantology and surgical dentistry.
In this context, SimplySilk occupies a timely and strategically important niche, combining long-lasting barrier function, high biocompatibility, and the elimination of animal tissue use.
SimplySilk already holds CE marking as a Class III medical device and is commercially available in Europe. Concurrently with the recertification process under MDR, Fibrothelium is preparing documentation for FDA submission, with a target to enter the U.S. market by 2027. Current clinical studies demonstrate the membrane’s high efficacy in standard clinical scenarios.
VIVOLTA CEO Denis Leissing emphasized that this partnership reflects the company’s ability to support innovative products through all stages — from concept to commercialization. He noted that combining Fibrothelium’s silk biomaterial with the high-throughput MediSpin technology will make SimplySilk accessible to patients worldwide.
In turn, Fibrothelium CEO Hans Lemhøyse described the collaboration with VIVOLTA as a key milestone in scaling production and global distribution of SimplySilk. According to him, VIVOLTA’s experience in manufacturing electrospun medical devices ensures confidence in the product’s quality, reproducibility, and scalability.
The partnership between VIVOLTA and Fibrothelium reflects a broader trend in modern dentistry and surgery — a shift toward high-tech, ethically neutral, and clinically predictable biomaterials. The SimplySilk membrane demonstrates how innovations in material science and manufacturing technologies can directly impact the quality of regenerative treatment.
В условиях растущего спроса на имплантационные и регенеративные процедуры такие решения способны задать новый стандарт направленной костной регенерации, сочетая безопасность, эффективность и комфорт для пациента.
The field of oncological dentistry and primary dental care is undergoing a profound transformation requiring a new integration of clinical
Modern dentistry is developing under conditions of rapid growth in clinical capabilities. New materials, digital technologies, imaging methods, and treatment
OTEXE.COM uses cookies to personalize the services and improve the usability of the site. If you do not want to use cookies, please disable them in your browser settings.
